Interplay of Hypoxia and A 2B Adenosine Receptors in Tissue Protection

Advances in Pharmacology

Volumn 61, Issue , 2011, Pages 145-186

  Koeppen, Michael ^a   Eckle, Tobias ^a   Eltzschig, Holger K ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Adenosine; Adenosine receptor; Hypoxia; Inflammation

Indexed keywords

ADENOSINE; ADENOSINE A2A RECEPTOR; ADENOSINE A2B RECEPTOR; ADENOSINE A3 RECEPTOR; HYPOXIA INDUCIBLE FACTOR; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE;

BOOK; HEART MUSCLE ISCHEMIA; HUMAN; HYPOXIA; INFLAMMATION; INTESTINE ISCHEMIA; ISCHEMIA; KIDNEY INJURY; LUNG INJURY; NONHUMAN; OXYGEN SENSING; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TISSUE REACTION; ANIMAL; ANOXIA; ANTIBODY SPECIFICITY; METABOLISM; PATHOLOGY; REVIEW;

ADENOSINE; ANIMALS; ANOXIA; HUMANS; INFLAMMATION; ORGAN SPECIFICITY; RECEPTOR, ADENOSINE A2B; SIGNAL TRANSDUCTION;

EID: 79955948343     PISSN: 10543589     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-385526-8.00006-0     Document Type: Chapter

References (238)

1. Abuelo J.G. Normotensive ischemic acute renal failure. The New England Journal of Medicine 2007, 357(8):797-805.
2. Aherne C.M., Kewley E.M., Eltzschig H.K. The resurgence of A2B adenosine receptor signaling. Biochimica et Biophysica Acta 2010, (in press).
3. Ahmad A., Ahmad S., Glover L., Miller S.M., Shannon J.M., Guo X., et al. Adenosine A2A receptor is a unique angiogenic target of HIF-2alpha in pulmonary endothelial cells. Proceedings of the National Academy of Sciences of the United States of America 2009, 106(26):10684-10689.
4. Andrade C.F., Kaneda H., Der S., Tsang M., Lodyga M., Chimisso Dos Santos C., et al. Toll-like receptor and cytokine gene expression in the early phase of human lung transplantation. The Journal of Heart and Lung Transplantation 2006, 25(11):1317-1323.
5. Aragones J., Fraisl P., Baes M., Carmeliet P. Oxygen sensors at the crossroad of metabolism. Cell Metabolism 2009, 9(1):11-22.
6. Aragones J., Schneider M., Van Geyte K., Fraisl P., Dresselaers T., Mazzone M., et al. Deficiency or inhibition of oxygen sensor Phd1 induces hypoxia tolerance by reprogramming basal metabolism. Nature Genetics 2008, 40(2):170-180.
7. Armstrong S., Ganote C.E. Adenosine receptor specificity in preconditioning of isolated rabbit cardiomyocytes: Evidence of A3 receptor involvement. Cardiovascular Research 1994, 28(7):1049-1056.
8. Auchampach J.A., Jin X., Moore J., Wan T.C., Kreckler L.M., Ge Z.D., et al. Comparison of three different A1 adenosine receptor antagonists on infarct size and multiple cycle ischemic preconditioning in anesthetized dogs. The Journal of Pharmacology and Experimental Therapeutics 2004, 308(3):846-856.
9. Baxter G.F. Role of adenosine in delayed preconditioning of myocardium. Cardiovascular Research 2002, 55:483-494.
10. Belperio J.A., Keane M.P., Burdick M.D., Londhe V., Xue Y.Y., Li K., et al. Critical role for CXCR2 and CXCR2 ligands during the pathogenesis of ventilator-induced lung injury. The Journal of Clinical Investigation 2002, 110(11):1703-1716.
11. Bishop T., Gallagher D., Pascual A., Lygate C.A., de Bono J.P., Nicholls L.G., et al. Abnormal sympathoadrenal development and systemic hypotension in PHD3-/-mice. Molecular and Cellular Biology 2008, 28(10):3386-3400.
12. Blackburn M.R. Too much of a good thing: Adenosine overload in adenosine-deaminase-deficient mice. Trends in Pharmacological Sciences 2003, 24(2):66-70.
13. Blackburn M.R., Vance C.O., Morschl E., Wilson C.N. Adenosine receptors and inflammation. Handbook of Experimental Pharmacology 2009, (193):215-269.
14. Blackburn M.R., Volmer J.B., Thrasher J.L., Zhong H., Crosby J.R., Lee J.J., et al. Metabolic consequences of adenosine deaminase deficiency in mice are associated with defects in alveogenesis, pulmonary inflammation, and airway obstruction. The Journal of Experimental Medicine 2000, 192(2):159-170.
15. Boutin A.T., Weidemann A., Fu Z., Mesropian L., Gradin K., Jamora C., et al. Epidermal sensing of oxygen is essential for systemic hypoxic response. Cell 2008, 133(2):223-234.
16. Bruns R.F. Adenosine receptor activation in human fibroblasts: Nucleoside agonists and antagonists. Canadian Journal of Physiology and Pharmacology 1980, 58(6):673-691.
17. Brusselmans K., Compernolle V., Tjwa M., Wiesener M.S., Maxwell P.H., Collen D., et al. Heterozygous deficiency of hypoxia-inducible factor-2{alpha} protects mice against pulmonary hypertension and right ventricular dysfunction during prolonged hypoxia. The Journal of Clinical Investigation 2003, 111(10):1519-1527.
18. Cai Z., Zhong H., Bosch-Marce M., Fox-Talbot K., Wang L., Wei C., et al. Complete loss of ischaemic preconditioning-induced cardioprotection in mice with partial deficiency of HIF-1{alpha}. Cardiovascular Research 2007, 77(3):463-470.
19. Carbia-Nagashima A., Gerez J., Perez-Castro C., Paez-Pereda M., Silberstein S., Stalla G.K., et al. RSUME, a small RWD-containing protein, enhances SUMO conjugation and stabilizes HIF-1alpha during hypoxia. Cell 2007, 131(2):309-323.
20. Carden D.L., Granger D.N. Pathophysiology of ischaemia-reperfusion injury. The Journal of Pathology 2000, 190(3):255-266.
21. Carmeliet P., Dor Y., Herbert J.M., Fukumura D., Brusselmans K., Dewerchin M., et al. Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 1998, 394(6692):485-490.
22. Casanello P., Torres A., Sanhueza F., Gonzalez M., Farias M., Gallardo V., et al. Equilibrative nucleoside transporter 1 expression is downregulated by hypoxia in human umbilical vein endothelium. Circulation Research 2005, 97(1):16-24.
23. Chaudary N., Naydenova Z., Shuralyova I., Coe I.R. Hypoxia regulates the adenosine transporter, mENT1, in the murine cardiomyocyte cell line, HL-1. Cardiovascular Research 2004, 61(4):780-788.
24. Chen Y., Corriden R., Inoue Y., Yip L., Hashiguchi N., Zinkernagel A., et al. ATP release guides neutrophil chemotaxis via P2Y2 and A3 receptors. Science 2006, 314(5806):1792-1795.
25. Cheng J., Kang X., Zhang S., Yeh E.T. SUMO-specific protease 1 is essential for stabilization of HIF1alpha during hypoxia. Cell 2007, 131(3):584-595.
26. Chu S., Ferro T.J. Sp1: Regulation of gene expression by phosphorylation. Gene 2005, 348:1-11.
27. Chunn J.L., Molina J.G., Mi T., Xia Y., Kellems R.E., Blackburn M.R. Adenosine-dependent pulmonary fibrosis in adenosine deaminase-deficient mice. Journal of Immunology 2005, 175(3):1937-1946.
28. Clark A.N., Youkey R., Liu X., Jia L., Blatt R., Day Y.J., et al. A1 adenosine receptor activation promotes angiogenesis and release of VEGF from monocytes. Circulation Research 2007, 101(11):1130-1138.
29. Colgan S.P., Eltzschig H.K., Eckle T., Thompson L.F. Physiological roles of 5'-ectonucleotidase (CD73). Purinergic Signalling 2006, 2(2):351-360.
30. Colgan S.P., Taylor C.T. Hypoxia: An alarm signal during intestinal inflammation. Nature Reviews. Gastroenterology & Hepatology 2010, 7(5):281-287.
31. Compernolle V., Brusselmans K., Acker T., Hoet P., Tjwa M., Beck H., et al. Loss of HIF-2alpha and inhibition of VEGF impair fetal lung maturation, whereas treatment with VEGF prevents fatal respiratory distress in premature mice. Natural Medicines 2002, 8(7):702-710.
32. Cramer T., Yamanishi Y., Clausen B.E., Forster I., Pawlinski R., Mackman N., et al. HIF-1alpha is essential for myeloid cell-mediated inflammation. Cell 2003, 112(5):645-657.
33. Cronstein B.N. Adenosine, an endogenous anti-inflammatory agent. Journal of Applied Physiology 1994, 76(1):5-13.
34. 2 generation, respectively. The Journal of Clinical Investigation 1990, 85(4):1150-1157.
35. Cronstein B.N., Eberle M.A., Gruber H.E., Levin R.I. Methotrexate inhibits neutrophil function by stimulating adenosine release from connective tissue cells. Proceedings of the National Academy of Sciences of the United States of America 1991, 88(6):2441-2445.
36. Cronstein B.N., Kramer S.B., Weissmann G., Hirschhorn R. Adenosine: A physiological modulator of superoxide anion generation by human neutrophils. The Journal of Experimental Medicine 1983, 158(4):1160-1177.
37. Cronstein B.N., Levin R.I., Philips M., Hirschhorn R., Abramson S.B., Weissmann G. Neutrophil adherence to endothelium is enhanced via adenosine A1 receptors and inhibited via adenosine A2 receptors. Journal of Immunology 1992, 148(7):2201-2206.
38. Cronstein B.N., Naime D., Ostad E. The antiinflammatory mechanism of methotrexate. Increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation. The Journal of Clinical Investigation 1993, 92(6):2675-2682.
39. Cronstein B., Rosenstein E., Kramer S., Weissmann G., Hirschhorn R. Adenosine: A physiologic modulator of superoxide anion generation by human neutrophils. Adenosine acts via an A2 receptor on human neutrophils. Journal of Immunology 1985, 135(2):1366-1371.
40. Cummins E.P., Seeballuck F., Keely S.J., Mangan N.E., Callanan J.J., Fallon P.G., et al. The hydroxylase inhibitor dimethyloxalylglycine is protective in a murine model of colitis. Gastroenterology 2008, 134(1):156-165.
41. Cummins E.P., Taylor C.T. Hypoxia-responsive transcription factors. Pflugers Archiv 2005, 450(6):363-371. Epub 2005 Jul 9.
42. Day Y.J., Huang L., McDuffie M.J., Rosin D.L., Ye H., Chen J.F., et al. Renal protection from ischemia mediated by A2A adenosine receptors on bone marrow-derived cells. The Journal of Clinical Investigation 2003, 112(6):883-891.
43. Day Y.J., Li Y., Rieger J.M., Ramos S.I., Okusa M.D., Linden J. A2A adenosine receptors on bone marrow-derived cells protect liver from ischemia-reperfusion injury. Journal of Immunology 2005, 174(8):5040-5046.
44. Day Y.J., Marshall M.A., Huang L., McDuffie M.J., Okusa M.D., Linden J. Protection from ischemic liver injury by activation of A2A adenosine receptors during reperfusion: Inhibition of chemokine induction. American Journal of Physiology. Gastrointestinal and Liver Physiology 2004, 286(2):G285-293.
45. Dayan F., Roux D., Brahimi-Horn M.C., Pouyssegur J., Mazure N.M. The oxygen sensor factor-inhibiting hypoxia-inducible factor-1 controls expression of distinct genes through the bifunctional transcriptional character of hypoxia-inducible factor-1alpha. Cancer Research 2006, 66(7):3688-3698.
46. De Perrot M., Sekine Y., Fischer S., Waddell T.K., McRae K., Liu M., et al. Interleukin-8 release during early reperfusion predicts graft function in human lung transplantation. American Journal of Respiratory and Critical Care Medicine 2002, 165(2):211-215.
47. Dejana E., Spagnuolo R., Bazzoni G. Interendothelial junctions and their role in the control of angiogenesis, vascular permeability and leukocyte transmigration. Thrombosis and Haemostasis 2001, 86(1):308-315.
48. Delacretaz E. Clinical practice. Supraventricular tachycardia. New England Journal of Medicine 2006, 354(10):1039-1051.
49. Dewald O., Frangogiannis N.G., Zoerlein M.P., Duerr G.D., Taffet G., Michael L.H., et al. A murine model of ischemic cardiomyopathy induced by repetitive ischemia and reperfusion. Thoracic and Cardiovascular Surgeon 2004, 52(5):305-311.
50. Dieterich H.J., Weissmuller T., Rosenberger P., Eltzschig H.K. Effect of hydroxyethyl starch on vascular leak syndrome and neutrophil accumulation during hypoxia. Critical Care Medicine 2006, 34(6):1775-1782.
51. Drury A.N., Szent-Gyorgyi A. The physiological activity of adenine compounds with especial reference to their action upon the mammalian heart. The Journal of Physiology 1929, 68(3):213-237.
52. Eckle T., Faigle M., Grenz A., Laucher S., Thompson L.F., Eltzschig H.K. A2B adenosine receptor dampens hypoxia-induced vascular leak. Blood 2008, 111(4):2024-2035.
53. Eckle T., Fullbier L., Grenz A., Eltzschig H.K. Usefulness of pressure-controlled ventilation at high inspiratory pressures to induce acute lung injury in mice. American Journal of Physiology. Lung Cellular and Molecular Physiology 2008, 295(4):L718-L724.
54. Eckle T., Fullbier L., Wehrmann M., Khoury J., Mittelbronn M., Ibla J., et al. Identification of ectonucleotidases CD39 and CD73 in innate protection during acute lung injury. Journal of Immunology 2007, 178(12):8127-8137.
55. Eckle T., Grenz A., Kohler D., Redel A., Falk M., Rolauffs B., et al. Systematic evaluation of a novel model for cardiac ischemic preconditioning in mice. American Journal of Physiology. Heart and Circulatory Physiology 2006, 291(5):H2533-H2540.
56. Eckle T., Grenz A., Laucher S., Eltzschig H.K. A2B adenosine receptor signaling attenuates acute lung injury by enhancing alveolar fluid clearance in mice. The Journal of Clinical Investigation 2008, 118(10):3301-3315.
57. Eckle T., Koeppen M., Eltzschig H.K. Role of extracellular adenosine in acute lung injury. Physiology (Bethesda) 2009, 24(5):298-306.
58. Eckle T., Kohler D., Lehmann R., El Kasmi K.C., Eltzschig H.K. Hypoxia-inducible factor-1 is central to cardioprotection: A new paradigm for ischemic preconditioning. Circulation 2008, 118(2):166-175.
59. Eckle T., Krahn T., Grenz A., Kohler D., Mittelbronn M., Ledent C., et al. Cardioprotection by ecto-5'-nucleotidase (CD73) and A2B adenosine receptors. Circulation 2007, 115(12):1581-1590.
60. Elliott M.R., Chekeni F.B., Trampont P.C., Lazarowski E.R., Kadl A., Walk S.F., et al. Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance. Nature 2009, 461(7261):282-286.
61. Eltzschig H.K. Adenosine: An old drug newly discovered. Anesthesiology 2009, 111(4):904-915.
62. Eltzschig H.K., Abdulla P., Hoffman E., Hamilton K.E., Daniels D., Schonfeld C., et al. HIF-1-dependent repression of equilibrative nucleoside transporter (ENT) in hypoxia. The Journal of Experimental Medicine 2005, 202(11):1493-1505.
63. Eltzschig H.K., Collard C.D. Vascular ischaemia and reperfusion injury. British Medical Bulletin 2004, 70(1):71-86.
64. Eltzschig H.K., Eckle T., Mager A., Kuper N., Karcher C., Weissmuller T., et al. ATP release from activated neutrophils occurs via connexin 43 and modulates adenosine-dependent endothelial cell function. Circulation Research 2006, 99(10):1100-1108.
65. Eltzschig H.K., Faigle M., Knapp S., Karhausen J., Ibla J., Rosenberger P., et al. Endothelial catabolism of extracellular adenosine during hypoxia: The role of surface adenosine deaminase and CD26. Blood 2006, 108(5):1602-1610.
66. Eltzschig H.K., Ibla J.C., Furuta G.T., Leonard M.O., Jacobson K.A., Enjyoji K., et al. Coordinated adenine nucleotide phosphohydrolysis and nucleoside signaling in posthypoxic endothelium: Role of ectonucleotidases and adenosine A2B receptors. The Journal of Experimental Medicine 2003, 198(5):783-796.
67. Eltzschig H.K., Kohler D., Eckle T., Kong T., Robson S.C., Colgan S.P. Central role of Sp1-regulated CD39 in hypoxia/ischemia protection. Blood 2009, 113(1):224-232.
68. Eltzschig H.K., Rivera-Nieves J., Colgan S.P. Targeting the A2B adenosine receptor during gastrointestinal ischemia and inflammation. Expert Opinion on Therapeutic Targets 2009, 13(11):1267-1277.
69. Eltzschig H.K., Thompson L.F., Karhausen J., Cotta R.J., Ibla J.C., Robson S.C., et al. Endogenous adenosine produced during hypoxia attenuates neutrophil accumulation: Coordination by extracellular nucleotide metabolism. Blood 2004, 104(13):3986-3992.
70. Enjyoji K., Sevigny J., Lin Y., Frenette P.S., Christie P.D., Esch J.S., et al. Targeted disruption of cd39/ATP diphosphohydrolase results in disordered hemostasis and thromboregulation. Natural Medicines 1999, 5(9):1010-1017.
71. Faigle M., Seessle J., Zug S., El Kasmi K.C., Eltzschig H.K. ATP release from vascular endothelia occurs across Cx43 hemichannels and is attenuated during hypoxia. PLoS One 2008, 3(7):e2801.
72. Feoktistov I., Ryzhov S., Zhong H., Goldstein A.E., Matafonov A., Zeng D., et al. Hypoxia modulates adenosine receptors in human endothelial and smooth muscle cells toward an A2B angiogenic phenotype. Hypertension 2004, 44(5):649-654.
73. Fraisl P., Aragones J., Carmeliet P. Inhibition of oxygen sensors as a therapeutic strategy for ischaemic and inflammatory disease. Nature Reviews. Drug Discovery 2009, 8(2):139-152.
74. Frangogiannis N.G., Ren G., Dewald O., Zymek P., Haudek S., Koerting A., et al. Critical role of endogenous thrombospondin-1 in preventing expansion of healing myocardial infarcts. Circulation 2005, 111(22):2935-2942.
75. Fredholm B.B. Adenosine, an endogenous distress signal, modulates tissue damage and repair. Cell Death and Differentiation 2007, 14(7):1315-1323.
76. Fredholm B.B., IJzerman A.P., Jacobson K.A., Klotz K.N., Linden J. International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacological Reviews 2001, 53(4):527-552.
77. Frick J.S., MacManus C.F., Scully M., Glover L.E., Eltzschig H.K., Colgan S.P. Contribution of adenosine A2B receptors to inflammatory parameters of experimental colitis. Journal of Immunology 2009, 182(8):4957-4964.
78. Gao Z.G., Jacobson K.A. Emerging adenosine receptor agonists. Expert Opinion on Emerging Drugs 2007, 12(3):479-492.
79. Gazoni L.M., Laubach V.E., Mulloy D.P., Bellizzi A., Unger E.B., Linden J., et al. Additive protection against lung ischemia-reperfusion injury by adenosine A2A receptor activation before procurement and during reperfusion. The Journal of Thoracic and Cardiovascular Surgery 2008, 135(1):156-165.
80. Gessi S., Fogli E., Sacchetto V., Merighi S., Varani K., Preti D., et al. Adenosine modulates HIF-1{alpha}, VEGF, IL-8, and foam cell formation in a human model of hypoxic foam cells. Arteriosclerosis, Thrombosis, and Vascular Biology 2010, 30(1):90-97.
81. Grenz A., Eckle T., Zhang H., Huang D.Y., Wehrmann M., Kohle C., et al. Use of a hanging-weight system for isolated renal artery occlusion during ischemic preconditioning in mice. American Journal of Physiology-Renal Physiology 2007, 292(1):F475-F485.
82. Grenz A., Osswald H., Eckle T., Yang D., Zhang H., Tran Z.V., et al. The reno-vascular A2B adenosine receptor protects the kidney from ischemia. PLoS Medicine 2008, 5(6):e137.
83. Grenz A., Zhang H., Eckle T., Mittelbronn M., Wehrmann M., Kohle C., et al. Protective role of ecto-5'-nucleotidase (CD73) in renal ischemia. Journal of the American Society of Nephrology 2007, 18(3):833-845.
84. Grenz A., Zhang H., Hermes M., Eckle T., Klingel K., Huang D.Y., et al. Contribution of E-NTPDase1 (CD39) to renal protection from ischemia-reperfusion injury. The FASEB Journal 2007, 21(11):2863-2873.
85. Grenz A., Zhang H., Weingart J., von Wietersheim S., Eckle T., Schnermann J.B., et al. Lack of effect of extracellular adenosine generation and signalling on renal erythropoietin secretion during hypoxia. American Journal of Physiology-Renal Physiology 2007, 293.
86. Grocott M.P., Martin D.S., Levett D.Z., McMorrow R., Windsor J., Montgomery H.E. Arterial blood gases and oxygen content in climbers on Mount Everest. The New England Journal of Medicine 2009, 360(2):140-149.
87. Haddad J.J. Science review: Redox and oxygen-sensitive transcription factors in the regulation of oxidant-mediated lung injury: Role for hypoxia-inducible factor-1alpha. Critical Care 2003, 7(1):47-54.
88. Haeberle H.A., Durrstein C., Rosenberger P., Hosakote Y.M., Kuhlicke J., Kempf V.A., et al. Oxygen-independent stabilization of hypoxia inducible factor (HIF)-1 during RSV infection. PLoS One 2008, 3(10):e3352.
89. Hart M.L., Gorzolla I.C., Schittenhelm J., Robson S.C., Eltzschig H.K. SP1-dependent induction of CD39 facilitates hepatic ischemic preconditioning. Journal of Immunology 2010, 184(7):4017-4024.
90. Hart M.L., Henn M., Kohler D., Kloor D., Mittelbronn M., Gorzolla I.C., et al. Role of extracellular nucleotide phosphohydrolysis in intestinal ischemia-reperfusion injury. The FASEB Journal 2008, 22(8):2784-2797.
91. Hart M.L., Jacobi B., Schittenhelm J., Henn M., Eltzschig H.K. Cutting edge: A2B adenosine receptor signaling provides potent protection during intestinal ischemia/reperfusion injury. Journal of Immunology 2009, 182(7):3965-3968.
92. Hart M.L., Kohler D., Eckle T., Kloor D., Stahl G.L., Eltzschig H.K. Direct treatment of mouse or human blood with soluble 5'-nucleotidase inhibits platelet aggregation. Arteriosclerosis, Thrombosis, and Vascular Biology 2008, 28(8):1477-1483.
93. Hart M.L., Much C., Gorzolla I.C., Schittenhelm J., Kloor D., Stahl G.L., et al. Extracellular adenosine production by ecto-5'-nucleotidase protects during murine hepatic ischemic preconditioning. Gastroenterology 2008, 135(5):1739-1750. e1733.
94. Hartmann G., Tschop M., Fischer R., Bidlingmaier C., Riepl R., Tschop K., et al. High altitude increases circulating interleukin-6, interleukin-1 receptor antagonist and C-reactive protein. Cytokine 2000, 12(3):246-252.
95. Hasko G., Cronstein B.N. Adenosine: An endogenous regulator of innate immunity. Trends in Immunology 2004, 25(1):33-39.
96. Hasko G., Csoka B., Nemeth Z.H., Vizi E.S., Pacher P. A(2B) adenosine receptors in immunity and inflammation. Trends in Immunology 2009, 30:263-270. Epub 2009, May 7.
97. Hasko G., Linden J., Cronstein B., Pacher P. Adenosine receptors: Therapeutic aspects for inflammatory and immune diseases. Nature Reviews. Drug Discovery 2008, 7(9):759-770.
98. Headrick J.P. Ischemic preconditioning: Bioenergetic and metabolic changes and the role of endogenous adenosine. Journal of Molecular and Cellular Cardiology 1996, 28(6):1227-1240.
99. Headrick J.P., Hack B., Ashton K.J. Acute adenosinergic cardioprotection in ischemic-reperfused hearts. American Journal of Physiology. Heart and Circulatory Physiology 2003, 285(5):H1797-1818.
100. Herrmann H.C. Update and rationale for ongoing acute myocardial infarction trials: Combination therapy, facilitation, and myocardial preservation. American Heart Journal 2006, 151(Suppl. 6):S30-39.
101. Hirota K., Semenza G.L. Regulation of hypoxia-inducible factor 1 by prolyl and asparaginyl hydroxylases. Biochemical and Biophysical Research Communications 2005, 338(1):610-616.
102. Hodgkiss R.J., Jones G., Long A., Parrick J., Smith K.A., Stratford M.R., et al. Flow cytometric evaluation of hypoxic cells in solid experimental tumours using fluorescence immunodetection. British Journal of Cancer 1991, 63(1):119-125.
103. Holmquist-Mengelbier L., Fredlund E., Lofstedt T., Noguera R., Navarro S., Nilsson H., et al. Recruitment of HIF-1alpha and HIF-2alpha to common target genes is differentially regulated in neuroblastoma: HIF-2alpha promotes an aggressive phenotype. Cancer Cell 2006, 10(5):413-423.
104. Hu C.J., Wang L.Y., Chodosh L.A., Keith B., Simon M.C. Differential roles of hypoxia-inducible factor 1alpha (HIF-1alpha) and HIF-2alpha in hypoxic gene regulation. Molecular and Cellular Biology 2003, 23(24):9361-9374.
105. Jacobson K.A., Gao Z.G. Adenosine receptors as therapeutic targets. Nature Reviews. Drug Discovery 2006, 5(3):247-264.
106. Jacobson K.A., Klutz A.M., Tosh D.K., Ivanov A.A., Preti D., Baraldi P.G. Medicinal chemistry of the A3 adenosine receptor: Agonists, antagonists, and receptor engineering. Handbook of Experimental Pharmacology 2009, (193):123-159.
107. Ji X., Kim Y.C., Ahern D.G., Linden J., Jacobson K.A. [3H]MRS 1754, a selective antagonist radioligand for A(2B) adenosine receptors. Biochemical Pharmacology 2001, 61(6):657-663.
108. Jordan J.E., Thourani V.H., Auchampach J.A., Robinson J.A., Wang N.P., Vinten-Johansen J. A(3) adenosine receptor activation attenuates neutrophil function and neutrophil-mediated reperfusion injury. The American Journal of Physiology 1999, 277(5 Pt. 2):H1895-1905.
109. Kaelin W.G. Proline hydroxylation and gene expression. Annual Review of Biochemistry 2005, 74:115-128.
110. Kaelin W.G. Von Hippel-Lindau disease. Annual Review of Pathology 2007, 2:145-173.
111. 2 sensing and cancer. Nature Reviews. Cancer 2008, 8(11):865-873.
112. Kaelin W.G., Ratcliffe P.J. Oxygen sensing by metazoans: The central role of the HIF hydroxylase pathway. Molecular Cell 2008, 30(4):393-402.
113. Karhausen J., Furuta G.T., Tomaszewski J.E., Johnson R.S., Colgan S.P., Haase V.H. Epithelial hypoxia-inducible factor-1 is protective in murine experimental colitis. The Journal of Clinical Investigation 2004, 114(8):1098-1106.
114. Karhausen J., Haase V.H., Colgan S.P. Inflammatory hypoxia: Role of hypoxia-inducible factor. Cell Cycle 2005, 4(2):256-258.
115. Karhausen J., Ibla J.C., Colgan S.P. Implications of hypoxia on mucosal barrier function. Cellular and Molecular Biology (Noisy-le-grand, France) 2003, 49(1):77-87.
116. Kempf V.A.J., Lebiedziejewski M., Alitalo K., Walzlein J.-H., Ehehalt U., Fiebig J., et al. Activation of hypoxia-inducible factor-1 in bacillary angiomatosis: Evidence for a role of hypoxia-inducible factor-1 in bacterial infections. Circulation 2005, 111(8):1054-1062.
117. Khoury J., Ibla J.C., Neish A.S., Colgan S.P. Antiinflammatory adaptation to hypoxia through adenosine-mediated cullin-1 deneddylation. The Journal of Clinical Investigation 2007, 117(3):703-711.
118. Kitakaze M., Hori M., Morioka T., Minamino T., Takashima S., Sato H., et al. Infarct size-limiting effect of ischemic preconditioning is blunted by inhibition of 5'-nucleotidase activity and attenuation of adenosine release. Circulation 1994, 89(3):1237-1246.
119. Kloner R.A., Rezkalla S.H. Preconditioning, postconditioning and their application to clinical cardiology. Cardiovascular Research 2006, 70(2):297-307.
120. Koeppen M., Eckle T., Eltzschig H.K. Selective deletion of the A1 adenosine receptor abolishes heart-rate slowing effects of intravascular adenosine in vivo. PLoS One 2009, 4(8):e6784.
121. Kohler D., Eckle T., Faigle M., Grenz A., Mittelbronn M., Laucher S., et al. CD39/ectonucleoside triphosphate diphosphohydrolase 1 provides myocardial protection during cardiac ischemia/reperfusion injury. Circulation 2007, 116(16):1784-1794.
122. Kong X., Lin Z., Liang D., Fath D., Sang N., Caro J. Histone deacetylase inhibitors induce VHL and ubiquitin-independent proteasomal degradation of hypoxia-inducible factor 1alpha. Molecular and Cellular Biology 2006, 26(6):2019-2028.
123. Kong T., Westerman K.A., Faigle M., Eltzschig H.K., Colgan S.P. HIF-dependent induction of adenosine A2B receptor in hypoxia. The FASEB Journal 2006, 20(13):2242-2250.
124. Kruger B., Krick S., Dhillon N., Lerner S.M., Ames S., Bromberg J.S., et al. Donor toll-like receptor 4 contributes to ischemia and reperfusion injury following human kidney transplantation. Proceedings of the National Academy of Sciences of the United States of America 2009, 106(9):3390-3395.
125. Kuhlicke J., Frick J.S., Morote-Garcia J.C., Rosenberger P., Eltzschig H.K. Hypoxia inducible factor (HIF)-1 coordinates induction of toll-like receptors TLR2 and TLR6 during hypoxia. PLoS One 2007, 2(12):e1364.
126. Kurtul N., Pence S., Akarsu E., Kocoglu H., Aksoy Y., Aksoy H. Adenosine deaminase activity in the serum of type 2 diabetic patients. Acta Medica (Hradec Kralove) 2004, 47(1):33-35.
127. Lankford A.R., Yang J.N., Rose'Meyer R., French B.A., Matherne G.P., Fredholm B.B., et al. Effect of modulating cardiac A1 adenosine receptor expression on protection with ischemic preconditioning. American Journal of Physiology. Heart and Circulatory Physiology 2006, 290(4):H1469-H1473.
128. Lappas C.M., Day Y.J., Marshall M.A., Engelhard V.H., Linden J. Adenosine A2A receptor activation reduces hepatic ischemia reperfusion injury by inhibiting CD1d-dependent NKT cell activation. The Journal of Experimental Medicine 2006, 203(12):2639-2648.
129. Lewis J.S., Lee J.A., Underwood J.C., Harris A.L., Lewis C.E. Macrophage responses to hypoxia: Relevance to disease mechanisms. Journal of Leukocyte Biology 1999, 66(6):889-900.
130. Licker M., de Perrot M., Spiliopoulos A., Robert J., Diaper J., Chevalley C., et al. Risk factors for acute lung injury after thoracic surgery for lung cancer. Anesthesia and Analgesia 2003, 97(6):1558-1565.
131. Linden J. Molecular approach to adenosine receptors: Receptor-mediated mechanisms of tissue protection. Annual Review of Pharmacology and Toxicology 2001, 41:775-787.
132. Linden J. Adenosine in tissue protection and tissue regeneration. Molecular Pharmacology 2005, 67(5):1385-1387.
133. Linden J. New insights into the regulation of inflammation by adenosine. The Journal of Clinical Investigation 2006, 116(7):1835-1837.
134. Linden J. Purinergic chemotaxis. Science 2006, 314(5806):1689-1690.
135. Loffler M., Morote-Garcia J.C., Eltzschig S.A., Coe I.R., Eltzschig H.K. Physiological roles of vascular nucleoside transporters. Arteriosclerosis, Thrombosis, and Vascular Biology 2007, 27(5):1004-1013.
136. Louis N.A., Robinson A.M., MacManus C.F., Karhausen J., Scully M., Colgan S.P. Control of IFN-alphaA by CD73: Implications for mucosal inflammation. Journal of Immunology 2008, 180(6):4246-4255.
137. Lukashev D.E., Smith P.T., Caldwell C.C., Ohta A., Apasov S.G., Sitkovsky M.V. Analysis of A2a receptor-deficient mice reveals no significant compensatory increases in the expression of A2b, A1, and A3 adenosine receptors in lymphoid organs. Biochemical Pharmacology 2003, 65(12):2081-2090.
138. Luscinskas F.W., Ma S., Nusrat A., Parkos C.A., Shaw S.K. Leukocyte transendothelial migration: A junctional affair. Seminars in Immunology 2002, 14(2):105-113.
139. Luscinskas F.W., Ma S., Nusrat A., Parkos C.A., Shaw S.K. The role of endothelial cell lateral junctions during leukocyte trafficking. Immunological Reviews 2002, 186:57-67.
140. Mahon P.C., Hirota K., Semenza G.L. FIH-1: A novel protein that interacts with HIF-1alpha and VHL to mediate repression of HIF-1 transcriptional activity. Genes & Development 2001, 15(20):2675-2686.
141. Mallick I.H., Yang W., Winslet M.C., Seifalian A.M. Ischemia-reperfusion injury of the intestine and protective strategies against injury. Digestive Diseases and Sciences 2004, 49(9):1359-1377.
142. Marcus A.J., Broekman M.J., Drosopoulos J.H.F., Islam N., Alyonycheva T.N., Safier L.B., et al. The endothelial cell ecto-ADPase responsible for inhibition of platelet function is CD39. The Journal of Clinical Investigation 1997, 99(6):1351-1360.
143. Martin T.R. Neutrophils and lung injury: Getting it right. The Journal of Clinical Investigation 2002, 110(11):1603-1605.
144. Mastrogiannaki M., Matak P., Keith B., Simon M.C., Vaulont S., Peyssonnaux C. HIF-2alpha, but not HIF-1alpha, promotes iron absorption in mice. The Journal of Clinical Investigation 2009, 119(5):1159-1166.
145. Matherne G.P., Linden J., Byford A.M., Gauthier N.S., Headrick J.P. Transgenic A1 adenosine receptor overexpression increases myocardial resistance to ischemia. Proceedings of the National Academy of Sciences of the United States of America 1997, 94(12):6541-6546.
146. Mazzone M., Dettori D., Leite de Oliveira R., Loges S., Schmidt T., Jonckx B., et al. Heterozygous deficiency of PHD2 restores tumor oxygenation and inhibits metastasis via endothelial normalization. Cell 2009, 136(5):839-851.
147. Merighi S., Benini A., Mirandola P., Gessi S., Varani K., Leung E., et al. A3 adenosine receptors modulate hypoxia-inducible factor-1alpha expression in human A375 melanoma cells. Neoplasia 2005, 7(10):894-903.
148. Mi T., Abbasi S., Zhang H., Uray K., Chunn J.L., Xia L.W., et al. Excess adenosine in murine penile erectile tissues contributes to priapism via A2B adenosine receptor signaling. The Journal of Clinical Investigation 2008, 118(4):1491-1501.
149. Michel C.C. Capillaries, caveolae, calcium and cyclic nucleotides: A new look at microvascular permeability. Journal of Molecular and Cellular Cardiology 1998, 30(12):2541-2546.
150. Michel C.C., Curry F.E. Microvascular permeability. Physiological Reviews 1999, 79(3):703-761.
151. Miki T., Miura T., Bunger R., Suzuki K., Sakamoto J., Shimamoto K. Ecto-5''-nucleotidase is not required for ischemic preconditioning in rabbit myocardium in situ. The American Journal of Physiology 1998, 275(4 Pt. 2):H1329-1337.
152. Milkiewicz M., Doyle J.L., Fudalewski T., Ispanovic E., Aghasi M., Haas T.L. HIF-1alpha and HIF-2alpha play a central role in stretch-induced but not shear-stress-induced angiogenesis in rat skeletal muscle. The Journal of Physiology 2007, 583(Pt. 2):753-766.
153. Milot J., Perron J., Lacasse Y., Letourneau L., Cartier P.C., Maltais F. Incidence and predictors of ARDS after cardiac surgery. Chest 2001, 119(3):884-888.
154. Moore T.M., Chetham P.M., Kelly J.J., Stevens T. Signal transduction and regulation of lung endothelial cell permeability. Interaction between calcium and cAMP. American Journal of Physiology 1998, 275:L203-222.
155. Morote-Garcia J.C., Rosenberger P., Kuhlicke J., Eltzschig H.K. HIF-1-dependent repression of adenosine kinase attenuates hypoxia-induced vascular leak. Blood 2008, 111:5571-5580.
156. Morote-Garcia J.C., Rosenberger P., Nivillac N.M., Coe I.R., Eltzschig H.K. Hypoxia-inducible factor-dependent repression of equilibrative nucleoside transporter 2 attenuates mucosal inflammation during intestinal hypoxia. Gastroenterology 2009, 136(2):607-618.
157. Morrison R.R., Talukder M.A., Ledent C., Mustafa S.J. Cardiac effects of adenosine in A(2A) receptor knockout hearts: Uncovering A(2B) receptors. American Journal of Physiology. Heart and Circulatory Physiology 2002, 282(2):H437-444.
158. Morrison R.R., Teng B., Oldenburg P.J., Katwa L.C., Schnermann J.B., Mustafa S.J. Effects of targeted deletion of A1 adenosine receptors on post-ischemic cardiac function and expression of adenosine receptor subtypes. American Journal of Physiology. Heart and Circulatory Physiology 2006, 291(4):H1875-H1882.
159. Mubagwa K., Flameng W. Adenosine, adenosine receptors and myocardial protection: An updated overview. Cardiovascular Research 2001, 52:25-39.
160. Murry C.E., Jennings R.B., Reimer K.A. Preconditioning with ischemia: A delay of lethal cell injury in ischemic myocardium. Circulation 1986, 74(5):1124-1136.
161. Naganuma M., Wiznerowicz E.B., Lappas C.M., Linden J., Worthington M.T., Ernst P.B. Cutting edge: Critical role for A2A adenosine receptors in the T cell-mediated regulation of colitis. Journal of Immunology 2006, 177(5):2765-2769.
162. Novak I. ATP as a signaling molecule: The exocrine focus. News in Physiological Sciences 2003, 18(1):12-17.
163. Odashima M., Bamias G., Rivera-Nieves J., Linden J., Nast C.C., Moskaluk C.A., et al. Activation of A2A adenosine receptor attenuates intestinal inflammation in animal models of inflammatory bowel disease. Gastroenterology 2005, 129(1):26-33.
164. Ogawa S., Gerlach H., Esposito C., Pasagian-Macaulay A., Brett J., Stern D. Hypoxia modulates the barrier and coagulant function of cultured bovine endothelium. Increased monolayer permeability and induction of procoagulant properties. The Journal of Clinical Investigation 1990, 85(4):1090-1098.
165. Ogawa S., Koga S., Kuwabara K., Brett J., Morrow B., Morris S.A., et al. Hypoxia-induced increased permeability of endothelial monolayers occurs through lowering of cellular cAMP levels. The American Journal of Physiology 1992, 262(3 Pt. 1):C546-554.
166. Ohta A., Sitkovsky M. Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage. Nature 2001, 414(6866):916-920.
167. Okusa M.D., Linden J., Huang L., Rosin D.L., Smith D.F., Sullivan G. Enhanced protection from renal ischemia-reperfusion [correction of ischemia:reperfusion] injury with A(2A)-adenosine receptor activation and PDE 4 inhibition. Kidney International 2001, 59(6):2114-2125.
168. Parikh C.R., Jani A., Mishra J., Ma Q., Kelly C., Barasch J., et al. Urine NGAL and IL-18 are predictive biomarkers for delayed graft function following kidney transplantation. American Journal of Transplantation 2006, 6(7):1639-1645.
169. Peng Z., Borea P.A., Wilder T., Yee H., Chiriboga L., Blackburn M.R., et al. Adenosine signaling contributes to ethanol-induced fatty liver in mice. The Journal of Clinical Investigation 2009, 119(3):582-594.
170. Percy M.J., Furlow P.W., Lucas G.S., Li X., Lappin T.R., McMullin M.F., et al. A gain-of-function mutation in the HIF2A gene in familial erythrocytosis. The New England Journal of Medicine 2008, 358(2):162-168.
171. Pinsky D.J., Broekman M.J., Peschon J.J., Stocking K.L., Fujita T., Ramasamy R., et al. Elucidation of the thromboregulatory role of CD39/ectoapyrase in the ischemic brain. The Journal of Clinical Investigation 2002, 109(8):1031-1040.
172. Rankin E.B., Biju M.P., Liu Q., Unger T.L., Rha J., Johnson R.S., et al. Hypoxia-inducible factor-2 (HIF-2) regulates hepatic erythropoietin in vivo. The Journal of Clinical Investigation 2007, 117(4):1068-1077.
173. Ratcliffe P.J. HIF-1 and HIF-2: Working alone or together in hypoxia?. The Journal of Clinical Investigation 2007, 117(4):862-865.
174. Reichelt M.E., Willems L., Molina J.G., Sun C.X., Noble J.C., Ashton K.J., et al. Genetic deletion of the A1 adenosine receptor limits myocardial ischemic tolerance. Circulation Research 2005, 96(3):363-367.
175. Resta R., Yamashita Y., Thompson L.F. Ecto-enzyme and signaling functions of lymphocyte CD73. Immunological Reviews 1998, 161:95-109.
176. Reutershan J., Cagnina R.E., Chang D., Linden J., Ley K. Therapeutic anti-inflammatory effects of myeloid cell adenosine receptor A2a stimulation in lipopolysaccharide-induced lung injury. Journal of Immunology 2007, 179(2):1254-1263.
177. Reutershan J., Morris M.A., Burcin T.L., Smith D.F., Chang D., Saprito M.S., et al. Critical role of endothelial CXCR2 in LPS-induced neutrophil migration into the lung. The Journal of Clinical Investigation 2006, 116(3):695-702.
178. Riess T., Andersson S.G.E., Lupas A., Schaller M., Schafer A., Kyme P., et al. Bartonella adhesin A mediates a proangiogenic host cell response. The Journal of Experimental Medicine 2004, 200(10):1267-1278.
179. Rius J., Guma M., Schachtrup C., Akassoglou K., Zinkernagel A.S., Nizet V., et al. NF-kappaB links innate immunity to the hypoxic response through transcriptional regulation of HIF-1alpha. Nature 2008, 153(7196):807-811.
180. Robinson A., Keely S., Karhausen J., Gerich M.E., Furuta G.T., Colgan S.P. Mucosal protection by hypoxia-inducible factor prolyl hydroxylase inhibition. Gastroenterology 2008, 134(1):145-155.
181. Robson S.C., Wu Y., Sun X., Knosalla C., Dwyer K., Enjyoji K. Ectonucleotidases of CD39 family modulate vascular inflammation and thrombosis in transplantation. Seminars in Thrombosis and Hemostasis 2005, 31(2):217-233.
182. Rose J.B., Naydenova Z., Bang A., Eguchi M., Sweeney G., Choi D.S., et al. Equilibrative nucleoside transporter 1 plays an essential role in cardioprotection. American Journal of Physiology - Heart and Circulatory Physiology 2010, 298(3):H771-H777.
183. Rosenberger C., Mandriota S., Jurgensen J.S., Wiesener M.S., Horstrup J.H., Frei U., et al. Expression of hypoxia-inducible factor-1alpha and -2alpha in hypoxic and ischemic rat kidneys. Journal of the American Society of Nephrology 2002, 13(7):1721-1732.
184. Rosenberger P., Schwab J.M., Mirakaj V., Masekowsky E., Mager A., Morote-Garcia J.C., et al. Hypoxia-inducible factor-dependent induction of netrin-1 dampens inflammation caused by hypoxia. Nature Immunology 2009, 10(2):195-202.
185. Rubenfeld G.D., Caldwell E., Peabody E., Weaver J., Martin D.P., Neff M., et al. Incidence and outcomes of acute lung injury. The New England Journal of Medicine 2005, 353(16):1685-1693.
186. Saadi S., Wrenshall L.E., Platt J.L. Regional manifestations and control of the immune system. The FASEB Journal 2002, 16(8):849-856.
187. Salvatore C.A., Tilley S.L., Latour A.M., Fletcher D.S., Koller B.H., Jacobson M.A. Disruption of the A(3) adenosine receptor gene in mice and its effect on stimulated inflammatory cells. The Journal of Biological Chemistry 2000, 275(6):4429-4434.
188. Sarnquist F.H. Physicians on Mount Everest. A clinical account of the 1981 American Medical Research Expedition to Everest. The Western Journal of Medicine 1983, 139(4):480-485.
189. Schingnitz U., Hartmann K., Macmanus C.F., Eckle T., Zug S., Colgan S.P., et al. Signaling through the A2B adenosine receptor dampens endotoxin-induced acute lung injury. Journal of Immunology 2010, 184(9):5271-5279.
190. Schneider D.J., Lindsay J.C., Zhou Y., Molina J.G., Blackburn M.R. Adenosine and osteopontin contribute to the development of chronic obstructive pulmonary disease. The FASEB Journal 2010, 24(1):70-80.
191. Schofield C.J., Ratcliffe P.J. Oxygen sensing by HIF hydroxylases. Nature Reviews. Molecular Cell Biology 2004, 5(5):343-354.
192. Schrier R.W., Wang W. Acute renal failure and sepsis. The New England Journal of Medicine 2004, 351(2):159-169.
193. Schulz R., Rose J., Post H., Heusch G. Involvement of endogenous adenosine in ischaemic preconditioning in swine. Pflugers Archiv 1995, 430(2):273-282.
194. Semenza G.L. Perspectives on oxygen sensing. Cell 1999, 98(3):281-284.
195. 2 homeostasis by hypoxia-inducible factor 1. Annual Review of Cell and Developmental Biology 1999, 15:551-578.
196. Semenza G.L. HIF-1, O(2), and the 3 PHDs: How animal cells signal hypoxia to the nucleus. Cell 2001, 107(1):1-3.
197. Semenza G.L. Targeting HIF-1 for cancer therapy. Nature Reviews. Cancer 2003, 3(10):721-732.
198. Semenza G.L. Life with oxygen. Science 2007, 318(5847):62-64.
199. Semenza G.L. Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene 2009, 29(5):625-634.
200. Sharma A.K., Laubach V.E., Ramos S.I., Zhao Y., Stukenborg G., Linden J., et al. Adenosine A2A receptor activation on CD4+ T lymphocytes and neutrophils attenuates lung ischemia-reperfusion injury. The Journal of Thoracic and Cardiovascular Surgery 2010, 139(2):474-482.
201. Sharma A.K., Linden J., Kron I.L., Laubach V.E. Protection from pulmonary ischemia-reperfusion injury by adenosine A2A receptor activation. Respiratory Research 2009, 10:58.
202. Shorr A.F., Abbott K.C., Agadoa L.Y. Acute respiratory distress syndrome after kidney transplantation: Epidemiology, risk factors, and outcomes. Critical Care Medicine 2003, 31(5):1325-1330.
203. Sitkovsky M.V. T regulatory cells: Hypoxia-adenosinergic suppression and re-direction of the immune response. Trends in Immunology 2009, 30(3):102-108.
204. Sitkovsky M.V., Kjaergaard J., Lukashev D., Ohta A. Hypoxia-adenosinergic immunosuppression: Tumor protection by T regulatory cells and cancerous tissue hypoxia. Clinical Cancer Research 2008, 14(19):5947-5952.
205. Sitkovsky M., Lukashev D. Regulation of immune cells by local-tissue oxygen tension: HIF1 alpha and adenosine receptors. Nature Reviews. Immunology 2005, 5(9):712-721.
206. Sitkovsky M.V., Lukashev D., Apasov S., Kojima H., Koshiba M., Caldwell C., et al. Physiological control of immune response and inflammatory tissue damage by hypoxia-inducible factors and adenosine A2A receptors. Annual Review of Immunology 2004, 22(1):657-682.
207. Stan R.V. Structure and function of endothelial caveolae. Microscopy Research and Technique 2002, 57:350-364.
208. Stevens T., Creighton J., Thompson W.J. Control of cAMP in lung endothelial cell phenotypes. Implications for control of barrier function. American Journal of Physiology 1999, 277:L119-L126.
209. Stevens T., Garcia J.G.N., Shasby D.M., Bhattacharya J., Malik A.B. Mechanisms regulating endothelial cell barrier function. American Journal of Physiology. Lung Cellular and Molecular Physiology 2000, 279:L419-L422.
210. Sun C.X., Zhong H., Mohsenin A., Morschl E., Chunn J.L., Molina J.G., et al. Role of A2B adenosine receptor signaling in adenosine-dependent pulmonary inflammation and injury. The Journal of Clinical Investigation 2006, 116(8):2173-2182.
211. Synnestvedt K., Furuta G.T., Comerford K.M., Louis N., Karhausen J., Eltzschig H.K., et al. Ecto-5'-nucleotidase (CD73) regulation by hypoxia-inducible factor-1 mediates permeability changes in intestinal epithelia. The Journal of Clinical Investigation 2002, 110(7):993-1002.
212. Takano H., Bolli R., Black R.G., Kodani E., Tang X.L., Yang Z., et al. A(1) or A(3) adenosine receptors induce late preconditioning against infarction in conscious rabbits by different mechanisms. Circulation Research 2001, 88(5):520-528.
213. Tambuwala M.M., Cummins E.P., Lenihan C.R., Kiss J., Stauch M., Scholz C.C., et al. Loss of prolyl hydroxylase-1 protects against colitis through reduced epithelial cell apoptosis and increased barrier function. Gastroenterology 2010, 139(6):2093-2101.
214. Taylor C.T. Interdependent roles for hypoxia inducible factor and nuclear factor-kappaB in hypoxic inflammation. The Journal of Physiology 2008, 586(Pt. 17):4055-4059.
215. Taylor C.T., Colgan S.P. Hypoxia and gastrointestinal disease. Journal of Molecular Medicine 2007, 85(12):1295-1300.
216. Thiel M., Chouker A., Ohta A., Jackson E., Caldwell C., Smith P., et al. Oxygenation inhibits the physiological tissue-protecting mechanism and thereby exacerbates acute inflammatory lung injury. PLoS Biology 2005, 3(6):e174.
217. Thompson L.F., Eltzschig H.K., Ibla J.C., Van De Wiele C.J., Resta R., Morote-Garcia J.C., et al. Crucial role for ecto-5'-nucleotidase (CD73) in vascular leakage during hypoxia. The Journal of Experimental Medicine 2004, 200(11):1395-1405.
218. Turnage R.H., Guice K.S., Oldham K.T. The effects of hypovolemia on multiple organ injury following intestinal reperfusion. Shock 1994, 1(6):408-412.
219. Van Linden A., Eltzschig H.K. Role of pulmonary adenosine during hypoxia: Extracellular generation, signaling and metabolism by surface adenosine deaminase/CD26. Expert Opinion on Biological Therapy 2007, 7(9):1437-1447.
220. Walmsley S.R., Print C., Farahi N., Peyssonnaux C., Johnson R.S., Cramer T., et al. Hypoxia-induced neutrophil survival is mediated by HIF-1{alpha}-dependent NF-{kappa}B activity. The Journal of Experimental Medicine 2005, 201(1):105-115.
221. Walsh M.C., Bourcier T., Takahashi K., Shi L., Busche M.N., Rother R.P., et al. Mannose-binding lectin is a regulator of inflammation that accompanies myocardial ischemia and reperfusion injury. Journal of Immunology 2005, 175(1):541-546.
222. 2 tension. Proceedings of the National Academy of Sciences of the United States of America 1995, 92(12):5510-5514.
223. Wang E.C.Y., Lee J.-M., Ruiz W.G., Balestreire E.M., von Bodungen M., Barrick S., et al. ATP and purinergic receptor-dependent membrane traffic in bladder umbrella cells. The Journal of Clinical Investigation 2005, 115(9):2412-2422.
224. Ware L.B., Matthay M.A. The acute respiratory distress syndrome. The New England Journal of Medicine 2000, 342(18):1334-1349.
225. Webb A.R. Capillary leak. Pathogenesis and treatment. Minerva Anestesiologica 2000, 66(5):255-263.
226. Weissmuller T., Eltzschig H.K., Colgan S.P. Dynamic purine signaling and metabolism during neutrophil-endothelial interactions. Purinergic Signalling 2005, 1(3):229-239.
227. 2 -regulated gene expression. The FASEB Journal 2002, 16(10):1151-1162.
228. Yalavarthy R., Edelstein C.L., Teitelbaum I. Acute renal failure and chronic kidney disease following liver transplantation. Hemodialysis International 2007, 11(Suppl. 3):S7-S12.
229. Yan S.F., Ogawa S., Stern D.M., Pinsky D.J. Hypoxia-induced modulation of endothelial cell properties: Regulation of barrier function and expression of interleukin-6. Kidney International 1997, 51(2):419-425.
230. Yang J.N., Chen J.F., Fredholm B.B. Physiological roles of A1 and A2A adenosine receptors in regulating heart rate, body temperature, and locomotion as revealed using knockout mice and caffeine. American Journal of Physiology. Heart and Circulatory Physiology 2009, 296(4):H1141-H1149.
231. Yang Z., Day Y.J., Toufektsian M.C., Ramos S.I., Marshall M., Wang X.Q., et al. Infarct-sparing effect of A2A-adenosine receptor activation is due primarily to its action on lymphocytes. Circulation 2005, 111(17):2190-2197.
232. Yang D., Koupenova M., McCrann D.J., Kopeikina K.J., Kagan H.M., Schreiber B.M., et al. The A2b adenosine receptor protects against vascular injury. Proceedings of the National Academy of Sciences of the United States of America 2008, 105(2):792-796.
233. Yang D., Zhang Y., Nguyen H.G., Koupenova M., Chauhan A.K., Makitalo M., et al. The A2B adenosine receptor protects against inflammation and excessive vascular adhesion. The Journal of Clinical Investigation 2006, 116(7):1913-1923.
234. Yu A.Y., Shimoda L.A., Iyer N.V., Huso D.L., Sun X., McWilliams R., et al. Impaired physiological responses to chronic hypoxia in mice partially deficient for hypoxia-inducible factor 1{alpha}. The Journal of Clinical Investigation 1999, 103(5):691-696.
235. Zheng W., Kuhlicke J., Jackel K., Eltzschig H.K., Singh A., Sjoblom M., et al. Hypoxia inducible factor-1 (HIF-1)-mediated repression of cystic fibrosis transmembrane conductance regulator (CFTR) in the intestinal epithelium. The FASEB Journal 2009, 23(1):204-213.
236. Zhong H., Shlykov S.G., Molina J.G., Sanborn B.M., Jacobson M.A., Tilley S.L., et al. Activation of murine lung mast cells by the adenosine A3 receptor. Journal of Immunology 2003, 171(1):338-345.
237. Zhou Y., Mohsenin A., Morschl E., Young H.W., Molina J.G., Ma W., et al. Enhanced airway inflammation and remodeling in adenosine deaminase-deficient mice lacking the A2B adenosine receptor. Journal of Immunology 2009, 182(12):8037-8046.
238. Zimmermann H. Extracellular metabolism of ATP and other nucleotides. Naunyn-Schmiedeberg's Archives of Pharmacology 2000, 362(4-5):299-309.